A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

NCT01194180 | Completed Phase 1 DMC

• 1 other identifier: TB023
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the BCG 'challenge' model a four-arm study design has been chosen. Twelve subjects will be recruited into each arm of the study. Allocation of BCG-naïve volunteers to either group A or B, and BCG-vaccinated volunteers to either group C or D, will be performed on a one-to-one alternating basis. Subjects in each group will be challenged by BCG administered intradermally. Prior to challenge, pre-existing immunity to TB will be induced by vaccination with BCG, MVA85A, and both in combination (when compared to BCG- \& MVA85A-naïve individuals). BCG quantification will be assessed by analysing the tissue obtained in a punch biopsy of volunteers' skin over the site of BCG 'challenge' vaccination. Any reduction in BCG quantification between groups will then be correlated to existing (and future) laboratory assays of vaccine-induced immune responses in order to identify potential immunological correlates of protection.

Conditions

Tuberculosis

Keywords

Mycobacterium tuberculosis; BCG; MVA85A

Outcome Measures

Primary Outcomes (1)

• Culture and RT-PCR quantification of BCG in challenge site biopsy

  10 weeks post biopsy

Secondary Outcomes (1)

• Established and exploratory markers of cell mediated immunity in blood samples and biopsied tissue

  10 weeks post biopsy

Study Arms (4)

Group A

EXPERIMENTAL

BCG-naive subjects receiving intradermal "challenge" injection of BCG and challenge site punch biopsy

Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu

Group B

EXPERIMENTAL

BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal "challenge" injection of BCG and challenge site punch biopsy

Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu

Group C

EXPERIMENTAL

BCG-experienced subjects receiving intradermal "challenge" injection of BCG and challenge site punch biopsy

Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu

Group D

EXPERIMENTAL

BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal "challenge" injection of BCG and challenge site punch biopsy

Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu

Interventions

BCG: 100 microlitres ~ 2-8 x 105 pfu BIOLOGICAL

BCG vaccination at day C (challenge day) then punch biopsy at day C+14

Group A; Group C

MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu BIOLOGICAL

MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14

Group B; Group D

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult aged 18-55 years
• Resident in or near Oxford for the duration of the study period
• No relevant findings in medical history or on physical examination
• Willingness to allow the Investigators to discuss the individual's medical history with their GP
• Willingness to use effective contraception for the duration of the study period (females only)
• Agreement to refrain from blood donation during the course of the study
• Willingness to give written informed consent
• Agreement to allow the Investigator to register volunteer details with a confidential database to prevent concurrent entry into clinical trials
• Able and willing (in the Investigator's opinion) to comply with all the study requirements
• Additional criteria to be met for subjects in group A:
• None
• Additional criteria to be met for subjects in group B:
• Willingness to use continuous effective barrier contraception for three months after receiving
• MVA85A vaccination (males and females)
• Additional criteria to be met for subjects in group C:

You may not qualify if:

• Clinical, radiological, or laboratory evidence of current active TB disease
• Laboratory evidence at screening of latent M. tb infection as indicated by a positive ELISPOT test (\>17 sfc/million PBMC) in any ESAT6 peptide or CFP10 peptide poola
• Previous vaccination with candidate TB vaccine MVA85A or candidate TB vaccine FP85A
• Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse
• History of serious psychiatric condition
• Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents
• History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study vaccine
• Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the volunteer in the studyb
• Positive HBsAg, HCV or HIV antibodies
• Female currently lactating, confirmed pregnancy or intention to become pregnant during study period
• Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the study vaccine for 60 days prior to dosing with the study vaccine, or planned use during the study period
• Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
• Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk or may influence the result of the study or may affect the volunteer's ability to participate in the study
• Previous vaccination with BCG
• Previous vaccination with a recombinant MVA vaccine other than MVA85A or FP85A

Sponsors & Collaborators

• University of Oxford: lead

Study Sites (1)

Centre for Clinical Vaccinology and Tropical Medicine

Oxford, Oxon, OX3 7LJ, United Kingdom

Location

Related Publications (2)

• Tanner R, Satti I, Harris SA, O'Shea MK, Cizmeci D, O'Connor D, Chomka A, Matsumiya M, Wittenberg R, Minassian AM, Meyer J, Fletcher HA, McShane H. Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection. Front Immunol. 2020 Jan 10;10:2983. doi: 10.3389/fimmu.2019.02983. eCollection 2019.

  PMID: 31998295 DERIVED

• Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner R, Minassian AM, Fletcher HA, McShane H. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. J Infect Dis. 2014 Apr 15;209(8):1259-68. doi: 10.1093/infdis/jit647. Epub 2013 Nov 23.

  PMID: 24273174 DERIVED

MeSH Terms

Conditions

Tuberculosis

Condition Hierarchy (Ancestors)

Mycobacterium Infections; Actinomycetales Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Study Officials

• Helen McShane

  University of Oxford

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 31, 2010
• First Posted: September 2, 2010
• Study Start: May 1, 2010
• Primary Completion: January 1, 2012
• Study Completion: January 1, 2012
• Last Updated: August 30, 2012

Record last verified: 2011-10

Locations

GB (1)